Greifswald, 06/22/2020

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed Companies Award' for the second time in a row.…

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential impact on the various Supply Chains and is committed to keep a transparent approach to all…

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding, following its last capital market transaction in May…

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of 100.0%.

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Schwerin/Greifswald (DE), 07/26/2019 – As part of her summer tour through Mecklenburg-Western Pomerania, Minister-President Manuela Schwesig stops by at the CHEPLAPHARM company headquarters in…

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year. Offering additional 150 million euros Term Loan B…